These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 28572020)

  • 21. Cognitive impairment in early-stage non-demented Parkinson's disease patients.
    Pfeiffer HC; Løkkegaard A; Zoetmulder M; Friberg L; Werdelin L
    Acta Neurol Scand; 2014 May; 129(5):307-18. PubMed ID: 24117192
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Everyday functioning of people with Parkinson's disease and impairments in executive function: a qualitative investigation.
    Kudlicka A; Hindle JV; Spencer LE; Clare L
    Disabil Rehabil; 2018 Oct; 40(20):2351-2363. PubMed ID: 28597694
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Psychometrics of the Montreal Cognitive Assessment (MoCA) and its subscales: validation of the Taiwanese version of the MoCA and an item response theory analysis.
    Tsai CF; Lee WJ; Wang SJ; Shia BC; Nasreddine Z; Fuh JL
    Int Psychogeriatr; 2012 Apr; 24(4):651-8. PubMed ID: 22152127
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cognitive impairment in patients with Parkinson's disease: A 30-month follow-up study.
    Chen L; Yu C; Zhang N; Liu J; Liu W
    Clin Neurol Neurosurg; 2016 Dec; 151():65-69. PubMed ID: 27816027
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Rapid communication: Preliminary validation of a telephone adapted Montreal Cognitive Assessment for the identification of mild cognitive impairment in Parkinson's disease.
    Benge JF; Kiselica AM
    Clin Neuropsychol; 2021 Jan; 35(1):133-147. PubMed ID: 32779959
    [No Abstract]   [Full Text] [Related]  

  • 26. Cognitive deterioration rates in patients with Parkinson's disease from northeastern China.
    Luo XG; Feng Y; Liu R; Yu HM; Wang L; Wu Z; Ren Y; He ZY
    Dement Geriatr Cogn Disord; 2010; 30(1):64-70. PubMed ID: 20689285
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Factor structure of the Montreal Cognitive Assessment in Parkinson disease.
    Smith CR; Cavanagh J; Sheridan M; Grosset KA; Cullen B; Grosset DG
    Int J Geriatr Psychiatry; 2020 Feb; 35(2):188-194. PubMed ID: 31736141
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Depressive Symptoms Negatively Impact Montreal Cognitive Assessment Performance: A Memory Clinic Experience.
    Blair M; Coleman K; Jesso S; Desbeaumes Jodoin V; Smolewska K; Warriner E; Finger E; Pasternak SH
    Can J Neurol Sci; 2016 Jul; 43(4):513-7. PubMed ID: 26842678
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Screening Mild and Major Neurocognitive Disorders in Parkinson's Disease.
    Lucza T; Karádi K; Kállai J; Weintraut R; Janszky J; Makkos A; Komoly S; Kovács N
    Behav Neurol; 2015; 2015():983606. PubMed ID: 26078489
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A comparison of montreal cognitive assessment between patients with visual hallucinations and without visual hallucinations in Parkinson's disease.
    Chung EJ; Seok K; Kim SJ
    Clin Neurol Neurosurg; 2015 Mar; 130():98-100. PubMed ID: 25596487
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Additional Queen Square (QS) screening items improve the test accuracy of the Montreal Cognitive Assessment (MoCA) after acute stroke.
    Chan E; Garritsen E; Altendorff S; Turner D; Simister R; Werring DJ; Cipolotti L
    J Neurol Sci; 2019 Dec; 407():116442. PubMed ID: 31677556
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Does the Montreal Cognitive Assessment (MoCA) identify cognitive impairment profiles in Parkinson's disease? An exploratory study.
    Castelli MB; Alonso-Recio L; Carvajal F; Serrano JM
    Appl Neuropsychol Adult; 2024; 31(3):238-247. PubMed ID: 34894908
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Development and initial testing of the Penn Parkinson's Daily Activities Questionnaire.
    Brennan L; Siderowf A; Rubright JD; Rick J; Dahodwala N; Duda JE; Hurtig H; Stern M; Xie SX; Rennert L; Karlawish J; Shea JA; Trojanowski JQ; Weintraub D
    Mov Disord; 2016 Jan; 31(1):126-34. PubMed ID: 26249849
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A recommended scale for cognitive screening in clinical trials of Parkinson's disease.
    Chou KL; Amick MM; Brandt J; Camicioli R; Frei K; Gitelman D; Goldman J; Growdon J; Hurtig HI; Levin B; Litvan I; Marsh L; Simuni T; Tröster AI; Uc EY;
    Mov Disord; 2010 Nov; 25(15):2501-7. PubMed ID: 20878991
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Decisional capacity for advanced care directives in Parkinson's disease with cognitive concerns.
    Abu Snineh M; Camicioli R; Miyasaki JM
    Parkinsonism Relat Disord; 2017 Jun; 39():77-79. PubMed ID: 28336349
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Longitudinal assessment of the pattern of cognitive decline in non-demented patients with advanced Parkinson's disease.
    Gasca-Salas C; Estanga A; Clavero P; Aguilar-Palacio I; González-Redondo R; Obeso JA; Rodríguez-Oroz MC
    J Parkinsons Dis; 2014; 4(4):677-86. PubMed ID: 25208730
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Relationship of circulatory BDNF with cognitive deficits in people with Parkinson's disease.
    Khalil H; Alomari MA; Khabour OF; Al-Hieshan A; Bajwa JA
    J Neurol Sci; 2016 Mar; 362():217-20. PubMed ID: 26944151
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Psychometrics and diagnostics of the Italian version of the Alternate Verbal Fluency Battery (AVFB) in non-demented Parkinson's disease patients.
    Aiello EN; Mameli F; Ruggiero F; Zirone E; Zago S; Piacentini S; Poletti B; Reitano MR; Santangelo G; Ticozzi N; Silani V; Priori A; Ferrucci R
    Neurol Sci; 2024 Aug; 45(8):3767-3774. PubMed ID: 38467953
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A holistic analysis of relationships between executive function and memory in Parkinson's disease.
    Alonso Recio L; Martín P; Carvajal F; Ruiz M; Serrano JM
    J Clin Exp Neuropsychol; 2013; 35(2):147-59. PubMed ID: 23289666
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The neuropsychological assessment battery categories test as a measure of executive dysfunction in patients with Parkinson's disease and essential tremor: an exploratory study.
    Benge J; Phillips-Sabol J; Phenis R
    Clin Neuropsychol; 2014; 28(6):1008-18. PubMed ID: 25181389
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.